studi
compar
perform
four
commerci
multiplex
pcr
assay
resplex
ii
panel
seeplex
xtag
rvp
xtag
rvp
fast
direct
fluoresc
antibodi
dfa
stain
viral
isol
seven
hundr
fifti
nasopharyng
swab
test
viral
agent
assay
sensit
specif
target
determin
composit
refer
standard
two
hundr
eightyeight
specimen
posit
dfa
viral
isol
addit
posit
multiplex
pcr
total
posit
rate
posit
specimen
one
viru
detect
specimen
two
three
four
four
one
case
compar
composit
refer
standard
interassay
accuraci
multiplex
pcr
assay
vari
superior
convent
diagnost
method
detect
broad
rang
respiratori
viral
agent
children
addit
sensit
two
commerci
assay
resplex
ii
plu
pre
seeplex
influenza
ab
subtyp
determin
rel
astra
influenza
screen
type
assay
detect
influenza
virus
includ
season
influenza
pandem
influenza
viru
use
posit
neg
nasopharyng
swab
influenza
astra
assay
sensit
seeplex
resplex
respect
specif
acut
viral
respiratori
tract
infect
signific
caus
morbid
mortal
children
particularli
compromis
immun
system
nucleic
acid
amplif
test
shown
superior
classic
diagnost
method
direct
fluoresc
antibodi
detect
dfa
viral
isol
identifi
broader
rang
virus
higher
sensit
specif
recent
sever
studi
demonstr
advantag
multiplex
pcr
simultan
detect
panel
virus
one
assay
studi
compar
sensit
specif
four
commerci
multiplex
pcr
assay
dfa
viral
isol
detect
respiratori
virus
children
ii
sensit
two
assay
resplex
ii
plu
pre
seeplex
influenza
ab
subtyp
astra
influenza
screen
type
assay
dfa
detect
season
pandem
influenza
viru
multiplex
assay
seven
hundr
fifti
nasopharyng
np
swab
select
children
birth
year
suspect
respiratori
tract
infect
seen
hospit
sick
children
toronto
canada
first
specimen
receiv
week
period
novemb
april
select
total
specimen
without
know
result
dfa
viral
isol
addit
specimen
chosen
manner
januari
march
nasopharyng
swab
flock
swab
copan
diagnost
murrieta
ca
usa
inocul
ml
univers
transport
medium
utmrt
copan
diagnost
murrieta
ca
usa
vortex
specimen
n
dispens
four
aliquot
store
nucleic
acid
extract
wherea
specimen
n
submit
nucleic
acid
extract
aliquot
freez
specimen
select
comparison
assay
detect
season
influenza
pandem
influenza
total
np
swab
specimen
select
aliquot
origin
specimen
frozen
receipt
influenza
posit
specimen
astra
screen
type
assay
season
influenza
infa
pandem
influenza
infa
influenza
ab
neg
specimen
astra
assay
specimen
made
anonym
delink
person
health
identifi
dfa
perform
use
fluorophorelabel
monoclon
antibodi
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
adenoviru
adv
infab
simulfluor
millipor
temecula
ca
usa
human
metapneumoviru
hmpv
diagnost
hybrid
athen
oh
usa
dfa
carri
target
per
manufactur
protocol
amplif
product
detect
use
liquichip
luminex
austin
tx
usa
resplex
ii
luminex
rvp
rvp
fast
qiagen
instruct
user
determin
appropri
cutoff
valu
test
platform
patient
popul
cutoff
valu
resplex
ii
determin
empir
sum
mean
mfi
plu
time
standard
deviat
neg
specimen
neg
assay
cutoff
valu
rvp
rvp
fast
predetermin
manufactur
assay
intern
control
ic
includ
rule
pcr
inhibit
tabl
show
target
characterist
multiplex
assay
detect
amplif
product
seeplex
assay
coupl
capillari
electrophoresi
technolog
tape
system
ltd
loanhead
uk
true
posit
target
except
bov
coronavirus
enteroviru
rhinoviru
posit
viral
cultur
posit
result
singl
target
two
dfa
four
molecular
assay
consid
true
posit
bov
coronavirus
enteroviru
rhinoviru
could
detect
dfa
viral
isol
true
posit
agent
defin
posit
result
least
two
three
four
multiplex
pcr
assay
distribut
respiratori
virus
viru
isol
perform
specimen
specimen
test
consid
true
posit
result
least
one
viru
dfa
cultur
pcr
specimen
posit
dfa
viral
isol
addit
posit
multiplex
pcr
singl
viru
detect
specimen
two
virus
three
four
specimen
four
virus
one
tabl
show
overal
distribut
respiratori
viral
pathogen
indic
predomin
enterovirusesrhinovirus
influenza
virus
rsv
also
show
parainfluenza
virus
hmpv
coronavirus
account
follow
bocaviru
adenoviru
around
among
dual
infect
n
enterorhinovirus
commonli
associ
virus
tripl
virusinfect
specimen
includ
adv
enterovirusrhinoviru
bov
n
adv
enterovirusrhinoviru
n
rsvb
bov
n
rsvb
enterovirusrhinoviru
n
uniqu
quadrupleag
infect
specimen
enterovirusrhinoviru
bov
n
comparison
sensit
specif
among
assay
sensit
specif
calcul
target
assay
accord
definit
true
fals
posit
tabl
viral
target
lump
togeth
necessari
perform
sensit
specif
analysi
ie
enterorhinoviru
coronavirus
tabl
indic
dfa
cultur
expect
less
sensit
pcr
target
howev
dfa
sensit
pcr
small
number
specif
target
assay
among
multiplex
assay
test
seeplex
sensit
detect
target
except
enterovirus
rhinovirus
multiplex
assay
good
sensit
detect
influenza
influenza
b
sensit
good
multiplex
assay
except
rvp
fast
superior
perform
seeplex
rsv
sensit
reflect
strong
perform
rsva
rsvb
wherea
decreas
sensit
assay
reflect
weaker
perform
either
target
ie
resplex
ii
rsva
rsvb
rvp
rsva
rsvb
similarli
variabl
sensit
individu
target
four
parainfluenza
virus
result
variat
overal
sensit
seeplex
show
good
sensit
four
type
resplex
ii
reduc
sensit
rvp
reduc
sensit
rvp
fast
reduc
sensit
sensit
detect
hmpv
good
seeplex
rvp
rvp
fast
accept
resplex
ii
howev
perform
adenoviru
import
respiratori
pathogen
variabl
rang
rvp
fast
seeplex
probabl
reflect
variat
serotyp
coverag
among
assay
addit
viral
agent
test
multiplex
assay
coronavirus
consist
detect
across
assay
except
cov
rvp
cov
rvp
fast
seeplex
rvp
fast
detect
bocaviru
infect
sensit
resplex
ii
detect
enteroviru
rhinoviru
inconsist
although
specif
target
multiplex
assay
proprietari
known
highli
conserv
region
region
either
rhinovirus
enterovirus
also
amplifi
member
genu
thu
assay
rvp
rvp
fast
assay
combin
enteroviru
rhinoviru
target
develop
specif
target
genu
outsid
region
may
compromis
sensit
detect
especi
rhinovirus
possibl
case
seeplex
assay
separ
enterovirus
rhinovirus
lower
sensit
assay
though
resplex
ii
assay
differenti
enterovirus
rhinovirus
occurr
posit
specimen
test
posit
target
suggest
may
crossreact
specif
excel
assay
use
composit
refer
standard
without
use
individu
singleplex
assay
adjud
singl
test
posit
determin
whether
slightli
lower
specif
observ
target
sever
assay
due
higher
sensit
detect
detect
fals
posit
multiplex
respiratori
panel
provid
clinician
diagnost
treatment
inform
manag
patient
case
influenza
knowledg
subtyp
import
respect
predict
activ
antivir
agent
adamantan
neuraminidas
inhibitor
addit
increas
sensit
number
virus
detect
multiplex
assay
permit
improv
identif
case
infect
multipl
agent
may
clinic
signific
especi
immun
compromis
individu
studi
found
two
virus
present
specimen
posit
specimen
bocaviru
coronavirus
virus
commonli
associ
multipl
agent
infect
follow
human
metapneumoviru
parainfluenza
virus
adenoviru
enterorhinovirus
influenza
ab
rsv
least
like
detect
presenc
anoth
viru
role
multipl
viral
agent
affect
clinic
cours
diseas
present
unknown
worthi
studi
respect
technic
perform
differ
multiplex
assay
follow
issu
identifi
seeplex
design
twostep
rtpcr
format
necessit
separ
rt
cdna
assay
though
new
onestep
procedur
develop
assay
requir
three
pcr
master
mix
five
target
one
plu
intern
control
also
assay
incorpor
posit
control
viral
target
consid
addit
qualiti
control
featur
assay
seeplex
assay
shortest
postpcr
step
especi
small
number
specimen
use
lab
screen
tape
system
maximum
five
specimen
per
run
contrast
resplex
ii
rvp
rvp
fast
use
microtitr
plate
format
luminex
platform
permit
high
throughput
analysi
practic
consider
laboratori
regard
feasibl
direct
indirect
cost
introduc
multiplex
molecular
test
respiratori
virus
led
rel
slow
routin
implement
methodolog
mahoni
et
al
shown
rvp
employ
firstlin
diagnost
tool
children
least
costli
strategi
compar
dfa
cultur
dfa
alon
dfa
plu
rvp
preval
infect
cost
molecular
test
offset
effici
use
labour
convent
dfa
cultur
save
healthcar
system
addit
test
hospit
avoid
knowledg
test
result
high
sensit
specif
oper
molecular
method
also
allow
virolog
laboratori
continu
function
even
event
viral
cultur
carri
due
biosafeti
issu
studi
newer
assay
version
multiplex
assay
resplex
ii
plu
panel
pre
target
seeplex
influenza
ab
subtyp
six
target
show
good
sensit
specif
rel
triplex
influenza
realtim
rtpcr
astra
influenza
screen
type
pandem
infa
viru
detect
import
tradit
season
subtyp
molecular
assay
react
pandem
strain
expect
pandem
strain
may
becom
predomin
circul
season
strain
immedi
postpandem
period
shown
multiplex
pcr
increas
sensit
detect
respiratori
virus
children
dfa
viral
isol
maintain
excel
specif
howev
import
develop
effect
clinic
laboratori
algorithm
time
optim
use
studi
impact
patient
care
differ
popul
differ
clinic
set
influenza
rsv
parainfluenza
viru
adenoviru
hmpv
well
establish
lead
caus
respiratori
infect
among
infant
children
howev
role
rhinovirus
enterovirus
bocaviru
coronavirus
copathogen
upper
respiratori
tract
infect
agent
lower
respiratori
tract
infect
less
well
investig
aid
studi
use
technolog
